View:
Download DOC
Download PDF
Download XLS

 

 

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

SCHEDULE 13G

 

Under the Securities Exchange Act of 1934

(Amendment No. 3)

 

lAVA THERAPEUTICS N.V.

(Name of Issuer)

 

Common Shares, par value $0.14 per share

(Title of Class of Securities)

 

 

                      N51517105                      

(CUSIP Number)

 

December 31, 2023

(Date of Event Which Requires Filing of this Statement)

 

Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

 

¨       Rule 13d-1(b)

 

x       Rule 13d-1(c)

 

¨       Rule 13d-1(d)

 

* The remainder of this cover page shall be filled out for a reporting person’s initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page.

 

The information required in the remainder of this cover page shall not be deemed to be “filed” for the purpose of Section 18 of the Securities Exchange Act of 1934 (“Act”) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

 

 

 

 

 

 

CUSIP No. N51517105

1

Name of Reporting Person

 

Redmile Group, LLC 

2

Check the Appropriate Box if a Member of a Group (See Instructions)

 

(a) ¨ 

(b) ¨ 

3 SEC Use Only
4

Citizenship or Place of Organization

 

Delaware 

 

 

number of
shares
beneficially
owned by
each
reporting
person with

 

 5

Sole Voting Power

 

0 

6

Shared Voting Power

 

2,074,372 (1) 

7

Sole Dispositive Power

 

0 

8

Shared Dispositive Power

 

2,074,372 (1) 

9

Aggregate Amount Beneficially Owned by Each Reporting Person

 

2,074,372 (1) 

10 Check if the Aggregate Amount in Row (9) Excludes Certain Shares (See Instructions)
11

Percent of Class Represented by Amount in Row (9)

 

7.9%(2) 

12

Type of Reporting Person (See Instructions)

 

IA, OO 

       

 

 

(1) Redmile Group, LLC’s beneficial ownership of the Issuer’s common shares (“Common Shares”) is comprised of 2,074,372 Common Shares owned by certain private investment vehicles managed by Redmile Group, LLC, including Redmile Biopharma Investments II, L.P., which Common Shares may be deemed beneficially owned by Redmile Group, LLC as investment manager of such private investment vehicles. The reported securities may also be deemed beneficially owned by Jeremy C. Green as the principal of Redmile Group, LLC. Redmile Group, LLC and Mr. Green each disclaim beneficial ownership of these shares, except to the extent of its or his pecuniary interest in such shares, if any.

(2) Percentage based on 26,289,087 Common Shares outstanding as of September 30, 2023 as reported by the Issuer in its Unaudited Condensed Consolidated Interim Financial Statements as of and for the Three and Nine Months Ended September 30, 2023 and 2022, an exhibit to the Form 6-K filed with the Securities and Exchange Commission on November 16, 2023 (the “Form 6-K”).

 

 

 

 

CUSIP No. N51517105

1

Name of Reporting Person

 

Jeremy C. Green 

2

Check the Appropriate Box if a Member of a Group (See Instructions)

 

(a) ¨ 

(b) ¨ 

3 SEC Use Only
4

Citizenship or Place of Organization

 

United Kingdom

 

 

number of
shares
beneficially
owned by
each
reporting
person with

 

 5

Sole Voting Power

 

0 

6

Shared Voting Power

 

2,074,372 (3) 

7

Sole Dispositive Power

 

0 

8

Shared Dispositive Power

 

2,074,372 (3) 

9

Aggregate Amount Beneficially Owned by Each Reporting Person

 

2,074,372 (3) 

10 Check if the Aggregate Amount in Row (9) Excludes Certain Shares (See Instructions)
11

Percent of Class Represented by Amount in Row (9)

 

7.9%(4) 

12

Type of Reporting Person (See Instructions)

 

IN, HC

       

 

 

(3) Jeremy C. Green’s beneficial ownership of Common Shares is comprised of 2,074,372 Common Shares owned by certain private investment vehicles managed by Redmile Group, LLC, including Redmile Biopharma Investments II, L.P., which Common Shares may be deemed beneficially owned by Redmile Group, LLC as investment manager of such private investment vehicles. The reported securities may also be deemed beneficially owned by Jeremy C. Green as the principal of Redmile Group, LLC. Redmile Group, LLC and Mr. Green each disclaim beneficial ownership of these shares, except to the extent of its or his pecuniary interest in such shares, if any.

(4) Percentage based on 26,289,087 Common Shares outstanding as of September 30, 2023, as reported by the Issuer in the Form 6-K.

 

 

 

 

CUSIP No. N51517105

1

Name of Reporting Person

 

Redmile Biopharma Investments II, L.P.

2

Check the Appropriate Box if a Member of a Group (See Instructions)

 

(a) ¨ 

(b) ¨ 

3 SEC Use Only
4

Citizenship or Place of Organization

 

Delaware

 

 

number of
shares
beneficially
owned by
each
reporting
person with

 

 5

Sole Voting Power

 

0 

6

Shared Voting Power

 

2,074,372

7

Sole Dispositive Power

 

0 

8

Shared Dispositive Power

 

2,074,372

9

Aggregate Amount Beneficially Owned by Each Reporting Person

 

2,074,372

10 Check if the Aggregate Amount in Row (9) Excludes Certain Shares (See Instructions)
11

Percent of Class Represented by Amount in Row (9)

 

7.9%(5) 

12

Type of Reporting Person (See Instructions)

 

PN

       

 

 

(5) Percentage based on 26,289,087 Common Shares outstanding as of September 30, 2023, as reported by the Issuer in the Form 6-K.

 

 

 

 

Item 1.

 

(a)       Name of Issuer

 

LAVA Therapeutics N.V.

 

(b)       Address of Issuer’s Principal Executive Offices

 

Yalelaan 62, 3584 CM Utrecht, The Netherlands

 

Item 2.

 

(a)       Names of Persons Filing

 

Redmile Group, LLC
Jeremy C. Green

Redmile Biopharma Investments II, L.P.

 

(b)       Address of Principal Business office or, if None, Residence

 

Redmile Group, LLC
One Letterman Drive
Building D, Suite D3-300
The Presidio of San Francisco
San Francisco, California 94129

 

Jeremy C. Green
c/o Redmile Group, LLC (NY Office)
45 W. 27th Street, Floor 11
New York, NY 10001

 

Redmile Biopharma Investments II, L.P.
c/o Redmile Group, LLC
One Letterman Drive
Building D, Suite D3-300
The Presidio of San Francisco
San Francisco, California 94129

 

(c)       Citizenship

 

Redmile Group, LLC: Delaware
Jeremy C. Green: United Kingdom

Redmile Biopharma Investments II, L.P.: Delaware

 

(d)        Title of Class of Securities

 

Common Shares, par value $0.14 per share

 

(e)       CUSIP Number

 

N51517105

 

 

 

 

Item 3.If this statement is filed pursuant to §§ 240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a:

 

(a)¨ Broker or dealer registered under section 15 of the Act (15 U.S.C. 78o);
     
(b)¨ Bank as defined in section 3(a)(6) of the Act (15 U.S.C. 78c);
     
(c)¨ Insurance company as defined in section 3(a)(19) of the Act (15 U.S.C. 78c);
     
(d)¨ Investment company registered under section 8 of the Investment Company Act of 1940 (15 U.S.C 80a-8);
     
(e)¨ An investment adviser in accordance with § 240.13d-1(b)(1)(ii)(E);
     
(f)¨ An employee benefit plan or endowment fund in accordance with § 240.13d-1(b)(1)(ii)(F);
     
(g)¨ A parent holding company or control person in accordance with § 240.13d-1(b)(1)(ii)(G);
     
(h)¨ A savings associations as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813);
     
(i)¨ A church plan that is excluded from the definition of an investment company under section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3);
     
(j)¨ A non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J);
     
(k)¨ Group, in accordance with § 240.13d-1(b)(1)(ii)(K). If filing as a non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J), please specify the type of institution: __________

 

Item 4.Ownership.

 

(a)       Amount beneficially owned:

 

Redmile Group, LLC – 2,074,372 (1)
Jeremy C. Green – 2,074,372 (1)

Redmile Biopharma Investments II, L.P. – 2,074,372 (2)

 

(b)       Percent of class:

 

Redmile Group, LLC – 7.9% (3)
Jeremy C. Green – 7.9% (3)

Redmile Biopharma Investments II, L.P. – 7.9% (3)

  

(c)       Number of shares as to which Redmile Group, LLC has:

 

(i)Sole power to vote or to direct the vote:

 

0

 

(ii)Shared power to vote or to direct the vote:

 

2,074,372 (1)

 

 

 

 

(iii)Sole power to dispose or to direct the disposition of:

 

0

 

(iv)Shared power to dispose or to direct the disposition of:

 

2,074,372 (1)

 

Number of shares as to which Jeremy C. Green has:

 

(i)Sole power to vote or to direct the vote:

 

0

 

(ii)Shared power to vote or to direct the vote:

 

2,074,372 (1)

 

(iii)Sole power to dispose or to direct the disposition of:

 

0

 

(iv)Shared power to dispose or to direct the disposition of:

 

2,074,372 (1)

 

Number of shares as to which Redmile Biopharma Investments II, L.P. has:

 

(i)Sole power to vote or to direct the vote:

 

0

 

(ii)Shared power to vote or to direct the vote:

 

2,074,372 (2)

 

(iii)Sole power to dispose or to direct the disposition of:

 

0

 

(iv)Shared power to dispose or to direct the disposition of:

 

2,074,372 (2)

 

(1)Redmile Group, LLC’s and Jeremy C. Green’s beneficial ownership of the Issuer’s Common Shares is comprised of 2,074,372 Common Shares owned by certain private investment vehicles managed by Redmile Group, LLC, including Redmile Biopharma Investments II, L.P., which Common Shares may be deemed beneficially owned by Redmile Group, LLC as investment manager of such private investment vehicles. The reported securities may also be deemed beneficially owned by Jeremy C. Green as the principal of Redmile Group, LLC. Redmile Group, LLC and Mr. Green each disclaim beneficial ownership of these shares, except to the extent of its or his pecuniary interest in such shares, if any.

 

(2)Redmile Biopharma Investments II, L.P.’s beneficial ownership of Common Shares is comprised of 2,074,372 Common Shares held directly by Redmile Biopharma Investments II, L.P.

 

(3)Percentage based on 26,289,087 Common Shares outstanding as of September 30, 2023, as reported by the Issuer in the Form 6-K.

 

 

 

 

Item 5.Ownership of Five Percent or Less of a Class.

 

If this statement is being filed to report the fact that as of the date hereof the reporting person has ceased to be the beneficial owner of more than 5 percent of the class of securities, check the following ¨

 

Item 6.Ownership of More than Five Percent on Behalf of Another Person.

 

N/A

 

Item 7.Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on By the Parent Holding Company or Control Person.

 

N/A

 

Item 8.Identification and Classification of Members of the Group.

 

N/A

 

Item 9.Notice of Dissolution of Group.

 

N/A

 

Item 10.Certifications.

 

By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under § 240.14a-11.

 

 

 

 

SIGNATURE

 

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

 

Date: February 14, 2024

 

  Redmile Group, LLC  
     
  By: /s/ Jeremy C. Green
    Name: Jeremy C. Green
Title: Managing Member

 

    /s/ Jeremy C. Green
    Jeremy C. Green  
     
  Redmile Biopharma Investments II, L.P.
  By: Redmile Biopharma Investments II (GP), LLC, its general partner  
     
  By: /s/ Jeremy C. Green
    Name: Jeremy C. Green
Title: Managing Member

 

 

 

 

Exhibit 99.1

 

Joint Filing Agreement

 

In accordance with Rule 13d-1(k)(1) under the Securities Exchange Act of 1934, as amended (the “Exchange Act”), the undersigned hereby agree to the joint filing on behalf of each of them of a Statement on Schedule 13G (including any and all amendments thereto, the “Schedule 13G”) relating to the Common Shares, $0.14 par value per share, of LAVA Therapeutics N.V., which may be deemed necessary pursuant to Regulation 13D or 13G promulgated under the Exchange Act.

 

The undersigned further agree that each party hereto is responsible for the timely filing of the Schedule 13G, and for the accuracy and completeness of the information concerning such party contained therein; provided, however, that no party is responsible for the accuracy or completeness of the information concerning any other party, unless such party knows or has a reason to believe that such information is inaccurate.

 

It is understood and agreed that a copy of this Joint Filing Agreement shall be attached as an exhibit to the Schedule 13G, filed on behalf of each of the parties hereto.

 

IN WITNESS WHEREOF, each of the undersigned has executed this Joint Filing Agreement as of the 14th day of February, 2024.

 

  REDMILE GROUP, LLC
   
  /s/ Jeremy C. Green   
  Name: Jeremy C. Green
  Title: Managing Member
   
  /s/ Jeremy C. Green                                                 
  JEREMY C. Green
   
  REDMILE BIOPHARMA INVESTMENTS II, L.P.
  By: Redmile Biopharma Investments II (GP), LLC, its general partner
   
  /s/ Jeremy C. Green   
  Name: Jeremy C. Green
  Title: Managing Member